Видео ютуба по тегу Medicines: Epcoritamab

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more
The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Epcoritamab - Blood Cancers OncTalk 2023
Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Epcoritamab - Blood Cancers OncTalk 2023
Subcutaneous epcoritamab in R/R B-cell NHL
Subcutaneous epcoritamab in R/R B-cell NHL
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Treatment Options of B-Cell Lymphoma: Glofitamab vs. Epcoritamab - Blood Cancer Video Library 2023
Treatment Options of B-Cell Lymphoma: Glofitamab vs. Epcoritamab - Blood Cancer Video Library 2023
Fixed duration epcoritamab with bendamustine and rituximab for first-line treatment of FL
Fixed duration epcoritamab with bendamustine and rituximab for first-line treatment of FL
The role of epcoritamab in third-line or later LBCL
The role of epcoritamab in third-line or later LBCL
Managing the adverse events associated with epcoritamab treatment: focus on CRS
Managing the adverse events associated with epcoritamab treatment: focus on CRS
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma - Blood Cancers OncTalk 2023
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma - Blood Cancers OncTalk 2023
Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD
Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD
EPCORE NHL-2: epcoritamab with rituximab and lenalidomide in newly diagnosed and R/R FL
EPCORE NHL-2: epcoritamab with rituximab and lenalidomide in newly diagnosed and R/R FL
Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD
Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD
Results of Phase I/II study of epcoritamab+R-DHAX/C in patients with R/R DLBCL eligible for autoSCT
Results of Phase I/II study of epcoritamab+R-DHAX/C in patients with R/R DLBCL eligible for autoSCT
EPCORE NHL-1 subgroup analyses: epcoritamab monotherapy in patients with R/R LBCL
EPCORE NHL-1 subgroup analyses: epcoritamab monotherapy in patients with R/R LBCL
Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma
Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma
Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC
Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC
Promising therapies for Richter's transformation: ven-R-CHOP, epcoritamab, pirtobrutinib & CAR-T
Promising therapies for Richter's transformation: ven-R-CHOP, epcoritamab, pirtobrutinib & CAR-T
Evaluating whether prior bendamustine exposure impacts the efficacy of epcoritamab in DLBCL
Evaluating whether prior bendamustine exposure impacts the efficacy of epcoritamab in DLBCL